摘要
目的观察氯吡格雷预防冠心病介入治疗后心血管不良事件发生的临床效果。方法选取2010—2011年于本院进行冠心病介入治疗的56例患者为研究对象,将其随机分为对照组和观察组,各28例,对照组术后给予低分子肝素皮下注射,观察组术前即给予氯吡格雷治疗,维持至术后6个月。将两组患者心血管不良事件发生率及用药前、用药后6h、12h、24h血小板聚集率、血栓素B2水平进行比较。结果观察组的心血管不良事件发生率低于对照组,用药后6h、12h、24h血小板聚集率、血栓素B2水平也均低于对照组,差异均有统计学意义(P<0.05)。结论氯吡格雷在预防冠心病介入治疗后心血管不良事件发生中的疗效更具优势,且其在控制血小板聚集率、血栓素B2水平方面也有积极的作用。
Objective To observe the efficacy of clopidogrel in the prevention of cardiovascular adverse events after coronary interventional treatment.Methods 56 patients from 2010 to 2011 at our hospital for percutaneous coronary intervention were chosen as the research object.They were randomly divided into control group and observation group,each 28 cases,the control group was treated with low molecular weight heparin subcutaneous injection,the observation group was given clopidogrel therapy before,to 6 months after surgery.The cardiovascular adverse events and medication before the medication,platelet aggregation rate and thromboxane B2 level for the two groups were compared after treatment 6h,12h,24h.Results The incidence of adverse cardiovascular events in the observation group was lower than the control group,the platelet aggregation rate,thromboxane B2 levels 6h,12h,24h after treatment were also lower than the control group,there were significant differences（P〈0.05）.Conclusion Clopidogrel in the efficacy for prevention of coronary heart disease intervention in the treatment of cardiovascular adverse events has advantages,and has positive effects of control platelet aggregation,thromboxane B2 levels.
出处
《实用心脑肺血管病杂志》
2013年第6期77-78,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
氯吡格雷
冠心病
介入治疗
心血管不良事件
Clopidogrel
Coronary disease
Interventional treatment
Adverse cardiovascular events
